PCM
ARRY

Palisade Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Palisade Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,000
Closed -$97K – 481
2016
Q4 		$97K Sell
11,000
-11,000
-50% -$80.9K ﹤0.01% 454
2016
Q3 		$148K Buy
+22,000
New +$85.1K 0.01% 551
2015
Q4 		– Sell
-20,000
Closed -$91K – 549
2015
Q3 		$91K Buy
+20,000
New +$119K ﹤0.01% 515

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Palisade Capital Management's ARRY Position: Q1 2017 in Review

Palisade Capital Management sold out of Array Biopharma Inc (ARRY) in Q1 2017, closing a stake of 11,000 shares — an estimated $97K sold.

Palisade Capital Management first reported a position in ARRY in Q3 2015 and held it in 3 quarters. The position peaked at $148K in Q3 2016. 187 funds tracked by Wall St. Rank hold ARRY as of Q1 2017.

  • Palisade Capital Management reported no remaining Array Biopharma Inc position as of Q1 2017 after selling out during the quarter.
  • Palisade Capital Management sold 11,000 Array Biopharma Inc shares in Q1 2017, an estimated $97K.
  • Palisade Capital Management first reported a position in Array Biopharma Inc in Q3 2015 and held it in 3 quarters.
  • Palisade Capital Management's Array Biopharma Inc position peaked at $148K in Q3 2016.
  • 187 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2017.

Based on Palisade Capital Management's 13F filing for Q1 2017, filed 19 Apr 2017.